LIWANLI Innovation Co., Ltd.
Taiwan Stock Exchange 3054.TW
LIWANLI Innovation Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 17.51%
-
LIWANLI Innovation Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was -343.82%, a -351.89% change year over year.
-
LIWANLI Innovation Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 136.49%, a 12,462.58% change year over year.
-
LIWANLI Innovation Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was -1.10%, a -104.79% change year over year.
-
LIWANLI Innovation Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 23.07%, a 110.79% change year over year.
| Date | EBITDA Margin | EBIT Margin | Depreciation and Amortization | EBIT |
|---|
| CEO | Li Ching Chen |
| IPO Date | Nov. 19, 2002 |
| Location | Taiwan |
| Headquarters | No. 258, Liancheng Road |
| Employees | 360 |
| Sector | Health Care |
| Industries | |
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry. It provides products in the areas of nutrition and healthcare. The company offers Vigoway and powder collection products for male, female, elderly, and children audience. Its products include probiotic enzymes, pro-active nutrients, resveratrol red grape extract, algae DHA soft gels, shea butter with type II collagen soft gels, algae astaxanthin Q10 soft gels, cordyceps militaries powder, tooth guard tablets, bovine and goat's milk bites, bilberry-tablets, DHA and vitamin D3 drops, and other products. The company was formerly known as Carry Technology International Co., Ltd. and changed its name to LIWANLI Innovation Co., Ltd. in 2015. LIWANLI Innovation Co., Ltd. was founded in 1980 and is based in New Taipei City, Taiwan.
Past 5 years
USD 1.10
USD 1.03
USD 0.86
USD 4.19
USD 0.68
StockViz Staff
January 15, 2025
Any question? Send us an email